A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis
Open Access
- 11 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
With the increasingly early stage lung squamous cell carcinoma (LUSC) being discovered, there is an urgent need for a comprehensive analysis of the prognostic characteristics of early stage LUSC. Here, we developed an immune-related gene signature for outcome prediction of early stage LUSC based on three independent cohorts. Differentially expressed genes (DEGs) were identified using CIBERSORT and ESTMATE algorithm. Then, a 17-immune-related gene (RPRM, APOH, SSX1, MSGN1, HPR, ISM2, FGA, LBP, HAS1, CSF2, RETN, CCL2, CCL21, MMP19, PTGIS, F13A1, C1QTNF1) signature was identified using univariate Cox regression, LASSO regression and stepwise multivariable Cox analysis based on the verified DEGs from 401 cases in The Cancer Genome Atlas (TCGA) database. Subsequently, a cohort of GSE74777 containing 107 cases downloaded from Gene Expression Omnibus (GEO) database and an independent data set consisting of 36 frozen tissues collected from National Cancer Center were used to validate the predictive value of the signature. Seventeen immune-related genes were identified from TCGA cohort, which were further used to establish a classification system to construct cases into high- and low-risk groups in terms of overall survival. This classifier was still an independent prognostic factor in multivariate analysis. In addition, another two independent cohorts and different clinical subgroups validated the significant predictive value of the signature. Further mechanism research found early stage LUSC patients with high risk had special immune cell infiltration characteristics and gene mutation profiles. In conclusion, we characterized the tumor microenvironment and established a highly predictive model for evaluating the prognosis of early stage LUSC, which may provide a lead for effective immunotherapeutic options tailored for each subtype.This publication has 70 references indexed in Scilit:
- Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 studyEuropean Journal of Cancer, 2015
- The 2015 World Health Organization Classification of Lung TumorsJournal of Thoracic Oncology, 2015
- Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivoMolecular Medicine Reports, 2015
- Use of a novel floxed mouse to characterise the cellular source of plasma coagulation FXIII-AThe Lancet, 2015
- Matrix Metalloproteinase-19 Promotes Metastatic BehaviorIn Vitroand Is Associated with Increased Mortality in Non–Small Cell Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2014
- SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcomaOncogene, 2013
- Reprimo (RPRM) Is a Novel Tumor Suppressor in Pituitary Tumors and Regulates Survival, Proliferation, and TumorigenicityEndocrinology, 2012
- An Integrated Proteomics and Metabolomics Approach for Defining Oncofetal Biomarkers in the Colorectal CancerAnnals of Surgery, 2012
- Expression and Immunotherapeutic Targeting of the SSX Family of Cancer–Testis Antigens in Prostate CancerCancer Research, 2011
- LKB1 modulates lung cancer differentiation and metastasisNature, 2007